2464 results about "Specific antibody" patented technology

The invention discloses development, preparation and application of a carbapenemase immunochromatography kit, and belongs to the technical field of biological medicines. According to comparison of amino acid sequences of five common carbapenemase variants of KPC, IMP, NDM, VIM and OXA48 types, the immunogen is prepared from conserved epitope sequences obtained respectively. A mouse is immunized, and a specific antibody pair which is strong in affinity and can be combined with multiple variants is obtained through multi-platform screening. On the basis, the carbapenemase quintuplet detection kit is developed by utilizing an immunochromatography method, has the advantages of high sensitivity, good specificity, capability of covering various drug-resistant variants, capability of detecting multiple targets at one time and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.

Provided are anti-PD-1 antibodies and trispecific antibodies specifically binding to PD-1, CTLA-4 and VEGF, or antigen-binding fragments thereof, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing.

The invention discloses a specific antibody capable of combining with a coronavirus SARS-CoV-2 and an SARS-CoV spike protein (SARS-CoV spike protein), and an application of the specific antibody capable of combining with the coronavirus SARS-CoV-2 and the SARS-CoV spike protein. The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention comprises CDRs with a specific sequence, can be specifically combined with SARS-CoV-2 and SARS-CoV spike protein, and has a relatively strong binding reaction with spike protein of another highly pathogenic coronavirus MERS-CoV at the same time. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an SARS-CoV and SARS-CoV-2 infection detection method.

The invention discloses an hMPV virus fusion protein F variant, an mRNA vaccine and application of the hMPV virus fusion protein F variant and the mRNA vaccine. The hMPV fusion protein F variant has amino acid residue difference on one or more sites relative to an hMPV fusion protein F with the login number of AGJ74096.1 in a GeneBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The mRNA vaccine designed based on the hMPV fusion protein F variant can induce a strong specific antibody reaction, the durability of the antibody in vivo is strong, the induced antibody can well neutralize an hMPV strain, the amplification of the hMPV in the lung is controlled, and the immune response of the hMPV in the lung is inhibited. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for preventing hMPV virus infection related diseases and developing multi-combined vaccines.

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.

The invention discloses a magnetic nano-enzyme probe and a preparation method thereof, a kit for detecting helicobacter pylori and application of the magnetic nano-enzyme probe, the core of the magnetic nano-enzyme probe is Fe3O4 nano-particles, magnetic enrichment capacity is provided, and interference of a complex matrix in a sample is eliminated; a layer of Pt nano-particles is electrostatically adsorbed through the cationic polymer to serve as a colorimetric interlayer, and a strong colorimetric signal is provided; au (at) Pt for modifying 5, 5 '-dithiobis (2-nitrobenzoic acid) is arranged on the surface layer and is used for providing strong catalytic signals and sites coupled with a large number of specific antibodies; meanwhile, the inner and outer layers of nano enzyme particles can synergistically enhance the catalytic action. The magnetic nano-enzyme probe disclosed by the invention has strong magnetic responsiveness, high colorimetric signal, strong catalytic activity and specific bacterium capturing capacity, realizes rapid enrichment and quantitative analysis of helicobacter pylori in a sample to be detected, eliminates matrix interference in practical application, and has high sensitivity and high specificity. The method has great potential in the aspects of high sensitivity and clinical monitoring of bacterial infection or pollution.

The invention relates to anti-drug neutralizing antibody analysis. In particular, the present application relates to methods for detecting neutralizing antibodies against a vascular endothelial growth factor (VEGF) binding moiety and a programmed cell death ligand-1 (PD-L1) binding moiety in a biological sample from an individual administered a bispecific antibody drug comprising the VEGF binding moiety.

The invention discloses preparation and application of an antibody capable of detecting various IMP variants, and belongs to the field of biological medicine. According to the invention, a conserved epitope sequence of IMP enzyme is obtained according to comparison of amino acid sequences of all IMP variants, and an antibody of a spatial epitope is prepared through structural analysis of the epitope. After a mouse is immunized with IMP immunogen protein, hybridoma cells secreting antibodies are obtained through multi-technology platform screening, specific antibody pairs MK35G9 and MK56G2 which are high in affinity and can be combined with multiple IMP variants are obtained after sequencing, and corresponding CDR is obtained through analysis. According to the present invention, the IMP enzyme detection product development is performed based on the immunochromatography platform, such that advantages of high sensitivity, good specificity, covering of a variety of IMP variants, and rapid and convenient detection are provided, and important help is provided for clinical auxiliary diagnosis and medication guidance.

The invention discloses a specific antibody MR-34 for targeting a coronavirus MERS-CoV spike protein RBD (Radial Basis Disease). The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, and can be specifically combined with an MERS-CoV spike protein RBD structural domain. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an MERS-CoV infection detection method.

The invention relates to the technical field of biology, in particular to a pseudorabies virus gD recombinant protein, a subunit vaccine and a preparation method and application thereof.The gD recombinant protein sequentially comprises a signal peptide, a connecting peptide, the 21st-350th site of the gD protein, an enzyme cutting site and a His tag from the N end to the C end, the amino acid sequence of the 21st-350th site of the gD protein is shown as SEQ ID No.4, and the amino acid sequence of the 21st-350th site of the gD protein is shown as SEQ ID No.6. The pseudorabies virus gD recombinant protein has high immunogenicity, the prepared subunit vaccine can generate a specific antibody with neutralizing activity, mice do not die after challenge, the protection rate is 100%, the protection rate after challenge of pigs is 100%, pathological sections only show slight pathological changes, and the pseudorabies virus gD recombinant protein has wide application prospects.

Provided are a bispecific antibody, a drug conjugate thereof, and a use thereof. The bispecific antibody comprises an EGFR binding domain and an HER3 binding domain. The provided bispecific antibody and the drug conjugate thereof have excellent endocytosis effects, proliferation inhibition activity and tumor growth inhibition activity, as well as good in vivo safety.

The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20) / anti-cluster of differentiation 3 (CD3) bispecific antibodies.

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

Relates to a multispecific antibody or antigen binding fragment specifically binding to LIGHT and GM-CSFR alpha, a composition containing the antibody or antigen binding fragment specifically binding to LIGHT and the antibody or antigen binding fragment specifically binding to GM-CSFR alpha, a pharmaceutical composition containing the multispecific antibody or composition, and a preparation method and application thereof. Including methods of using the same to prevent and treat inflammatory, respiratory or autoimmune diseases.

The invention belongs to the field of biological medicine, and relates to a pharmaceutical composition of an anti-CD3 * CD20 bispecific antibody, in particular to a liquid preparation and a freeze-dried preparation of the bispecific antibody and medical application of the liquid preparation and the freeze-dried preparation. More specifically, the pharmaceutical composition contains an anti-CD3 * CD20 bispecific antibody, a buffer solution, a stabilizer and a surfactant, the pH value of the pharmaceutical composition is about 4.5-6.5, and the pharmaceutical composition has good stability.

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.

The present invention relates to the field of tumor treatment and immunology biology. Provided are a pharmaceutical combination containing an anti-PD-1-anti-VEGFA bispecific antibody, and the use thereof. Specifically, the pharmaceutical combination comprises at least one bispecific antibody and at least one PARP inhibitor, wherein the bispecific antibody comprises a first protein functional region for targeting PD-1 and a second protein functional region for targeting VEGFA; and according to the EU numbering system, the heavy chain constant region of an immunoglobulin contained in the bispecific antibody is mutated at two sites, i.e. site 234 and site 235, and after mutation, the affinity constant of the bispecific antibody to FcγRI, FcγRIIa, FcγRIIIa and / or C1q is reduced compared with the affinity constant of the bispecific antibody thereto before mutation. The combined administration of the PARPi and the bispecific antibody has a significantly better therapeutic effect on tumors than the individual use of the PARPi or the bispecific antibody; and the present invention has good application prospects.

The invention discloses a novel microecological preparation composition for preventing and treating feline plague and application of the novel microecological preparation composition, and belongs to the technical field of microecological preparations. The recombinant lactobacillus plantarum NC8-VP2 constructed by a genetic engineering means can efficiently express the feline plague VP2 protein, and finally, a protective antigen expressed by the recombinant lactobacillus plantarum efficiently stimulates an organism to generate a specific antibody, so that the feline plague is prevented, and the use of chemical drugs is reduced. Recombinant escherichia coli BL21-pET32a-MLT constructed by the research can secrete and express melittin (MLT), large-scale production of melittin is realized, melittin and recombinant lactobacillus plantarum NC8-VP2 are further taken as active ingredients, a novel microecological preparation composition for preventing and controlling feline plague is developed and prepared, the morbidity of feline plague can be reduced, clinical symptoms of sick animals can be improved, and the novel microecological preparation composition has a good application prospect. Therefore, the compound has a relatively good application prospect in the aspect of preventing and treating feline plague.

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.

The invention provides an affinity carrier net for a cryoelectron microscope and a preparation method and application of a frozen sample of the affinity carrier net. The affinity carrier net comprises a carbonaceous bearing membrane covering the carrier net, a small organic molecule pyr-NHS connected with the carbonaceous bearing membrane, and a specific antibody protein connected with the small organic molecule pyr-NHS; the carbonaceous bearing film is a graphene film, a graphene oxide film or a carbon film. The method comprises the following steps: performing fusion expression on a PA tag having strong affinity interaction with an NZ-1 antibody on a target protein, and performing mixed incubation on an affinity carrier net fixed with an NZ-1 antibody protein and a cell lysis solution of the target protein which performs fusion expression on the PA tag; according to the method, efficient affinity purification and direct cryoelectron microscope sample preparation of the target protein with the PA tag in the cell lysis solution are realized, data collection and high-resolution structural analysis are carried out, the sample purification time and steps are reduced, the sample integrity is improved, the sample demand is reduced, and meanwhile, the problem of orientation tendency of sample distribution is solved.

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

Reported herein is, inter alia, a method for producing a trivalent bispecific antibody, the method comprising the steps of culturing a mammalian cell comprising a deoxyribonucleic acid encoding the trivalent bispecific antibody, and recovering the trivalent bispecific antibody from the cell or culture medium, wherein the deoxyribonucleic acid encoding the trivalent bispecific antibody is stably integrated into the genome of the mammalian cell and comprises in the 5' to 3' direction a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a first light chain, a fourth expression cassette encoding the first light chain, a fifth expression cassette encoding the second heavy chain, a sixth expression cassette encoding the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain, wherein the first heavy chain The chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain and a CL domain, the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site.

An anti-Nectin-4 single-domain antibody and the use thereof. Provided are a single-domain antibody specifically targeting Nectin-4, and amino acid sequences of a framework region FR and a complementarity-determining region CDR of a VHH chain thereof. The anti-Nectin-4 single-domain antibody can bind to a Nectin-4 antigen. An antibody-drug conjugate and a multi-specific antibody targeting the Nectin-4 target prepared by means of using the single-domain antibody have an excellent activity and high therapeutic efficacy.

The invention relates to the technical field of pesticide detection, and discloses a multi-component colloidal gold test strip for rapid detection of organophosphorus as well as a preparation method and application thereof, the preparation method comprises the following steps: preparing a specific antibody of the organophosphorus, and preparing a colloidal gold solution at the same time; mixing and incubating the specific antibody and a colloidal gold solution to obtain an antibody-labeled colloidal gold solution; pre-treating a detection pad, and immersing the detection pad in the antibody-labeled colloidal gold solution to obtain an impregnated pad; and sequentially assembling the dried dipping pad, a water absorption pad, a sample pad and a combination pad on a bottom plate to form a complete test strip. By improving the preparation process of the antibody and the assembly technology of the test strip, the detection sensitivity and specificity are remarkably improved. The test strip is simple and convenient in preparation process, high in cost benefit and convenient for large-scale production. In addition, the test strip is convenient to use and does not need to depend on professional equipment or technicians, and the detection result is visual and convenient to read.

The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin / kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-COA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact.The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.

The present technology provides antibodies specific to alkaline phosphatase, placental (ALPP) and / or alkaline phosphatase, placental-like 2 (ALPPL2), antigen-binding fragments thereof, and antibody-drug conjugates (ADCs) that can be employed as potential therapeutics for the treatment of diseases including cancer.

The invention discloses a pig sperm specific antibody. The coding sequence of the antibody is shown as any one of SEQ ID No: 1-3. According to the method, the nano antibody library is prepared by immunizing alpaca with whole pig sperms, and then the antibody capable of being specifically combined with the X or Y sperms can be screened out through the library, so that sorting of the X and Y sperms is realized. The screened antibody is a nano antibody, the size of the nano antibody is only 10% of that of a traditional antibody, the structure is simpler, the advantages of high stability, strong specificity and low immunogenicity are achieved, large-scale expression of the antibody can be achieved, the production cost of the antibody is greatly reduced, and industrial application is facilitated.

The invention discloses a silicon shell protected magnetic quantum dot nanoprobe, a preparation method, a kit and application. The nanoprobe comprises a nanomaterial and a specific antibody, the nanometer material is of a core-shell structure, and the outer surface of a core is sequentially coated with an interlayer and a protective shell layer outwards. The interlayer comprises a multi-layer laminated structure formed by alternately arranging a plurality of layers of positive electricity interlayers and negative electricity interlayers; the positive electric interlayer is polyethyleneimine, the negative electric interlayer is quantum dots, the quantum dots are CdSe / ZnS or carbon quantum dots, amino groups on the surface of the shell layer and a dialkynyl polyethylene ethanol solution are subjected to general coupling of specific antibodies in a click chemistry mode by taking diyne molecules as connecting arms. The magnetic nanoprobe with the core-shell structure not only has strong magnetic responsiveness and a high fluorescence signal, but also can adapt to a complex environment, after the magnetic nanoprobe is integrated with an immunochromatography test strip, to-be-detected targets including pathogenic bacteria and inflammatory markers can be rapidly captured in a whole blood sample at the same time, and the magnetic nanoprobe has huge application potential in early diagnosis of sepsis.